

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Ranexa Clinical Edit
<b>First Implementation Date:</b>	June 13, 2007
<b>Proposed Date:</b>	September 16, 2021
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Ranexa® (ranolazine)

**Why Issue Selected:** Ranexa® (ranolazine) was initially FDA approved in 2006. Ranexa is indicated for the treatment of chronic angina. According to the 2012 American College of Cardiology Foundation/American Heart Association guidelines for patients with stable ischemic heart disease, Ranexa may be useful when prescribed as a substitute for beta-blockers for relief of symptoms if initial treatment with beta-blockers leads to unacceptable side effects, is less effective, or if initial treatment with beta-blockers is contraindicated. The guidelines also state Ranexa may be used in combination with beta-blockers for relief of symptoms when initial treatment with beta-blockers is not successful. The mechanism of action of Ranexa's antianginal effects has not been determined. First line therapies for chronic angina include nitrates, beta-blockers, and calcium channel blockers; therapy with Ranexa should be reserved as a second line therapy.

Program-Specific Information:	Date Range FFS 7-1-2020 to 6-30-2021			
	Drug	Claims	Spend	Avg spend per claim
	RANEXA ER 500 MG TABLET	3,986	\$86,348.75	\$21.24
	RANEXA ER 1,000 MG TABLET	1,886	\$57,941.48	\$30.72

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Ranexa® (ranolazine)
- Age range: All appropriate MO HealthNet participants aged 18 years and older

## Approval Criteria

- Participant aged 18 years or older **AND**

- Documented compliance to previous ranolazine therapy (defined as 90 days in the past 120 days)  
**OR**
- Documented trial of a nitrate, beta-blocker, or calcium channel blocker (defined as 30 days in the past year)

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Documented history of significant hepatic impairment

## Required Documentation

Laboratory Results:  
MedWatch Form:


Progress Notes:  
Other:

X

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

1 year

## References

- RANEXA® (ranolazine) [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2020.
- Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012;126(25):3097-3137.[\[PubMed 23166210\]](#)
- Facts & Comparisons. Ranolazine Oral. Accessed August 5, 2020.